Slide 1: Earnings Presentation Second Quarter 2026
Earnings Presentation Second Quarter 2026 Nasdaq: NAGE | August 4, 2026
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation and other written or oral statements made from time to time by representatives of Niagen Bioscience contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act
Slide 3: Table of Contents & Leadership Team
Table of Contents & Leadership Team 1. Highlights Rob Fried Ozan Pamir Andrew Shao 2. Financial Results Chief Executive Officer Chief Financial Officer SVP, Global Regulatory & Scientific Affairs 3.Scientific Updates Carlos Lopez Michiko Kelley 4.Contact Information SVP, General Counsel Chief Market
Slide 4: Second Quarter 2026 Highlights
Second Quarter 2026 Highlights $29.8 million net sales 64.8% gross profit margin $1.0 million net income Diluted EPS of $0.01 $3.0 million Adjusted EBITDA(1) $66.7 million cash, no outstanding borrowings (1) See slide 12 for the non-GAAP reconciliation 4
Slide 5: World's Leading NAD+ Platform
World’s Leading NAD+ Platform CORE BUSINESS INJECTABLE & TELEHEALTH SKINCARE PHARMACEUTICAL Branded products Infusions Branded topical products and upcoming Drug development for treatment of rare Ingredient partners Injectables partnerships with large skincare companies genetic diseases 5
Slide 6: Executing Long-Term Strategic Growth Initiatives
Executing Long-Term Strategic Growth Initiatives Key strategic initiatives during Q2 2026. Consumer Products • Direct-to-consumer sales on the Company’s website grew by 23% year-over-year. • Completed and sold out of the pilot launch of the first skincare product, Nanocloud™. Niagen Plus • Launched
Slide 7: Q2 2026: Investing for Long-Term Growth While Maintaining Financial Discipline
Q2 2026: Investing for Long-Term Growth While Maintaining Financial Discipline Net Gross Net Cash Sales Margin Income Generation QTD Q2 2026 QTD Q2 2026 QTD Q2 2026 YTD Q2 2026 $29.8M 64.8% $1.0M $1.6M Tru Niagen $24.2M Adj. EBITDA(1) $3.0M Cash from operations Cash & Liquidity 2026 Financial Priori
Slide 8: Financial Highlights
Financial Highlights The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019)
Slide 9: Q2 2026 Net Sales: $29.8M
Q2 2026 Net Sales: $29.8M Total Company: Total Company, excluding divested segment: $31.1M Q2 2026 Q2 2025 $29.8M Tru Niagen $24.2M $22.7M $30.3M $29.8M 16% E-Commerce $20.5M $18.1M 16% 19% 20% Watson's & Other B2B $3.6M $4.6M 12% 12% 15% Niagen Ingredients $5.4M $7.4M 15% 69% Food-grade Niagen® $4.
Slide 10: 2025 – 2026 Net Sales Summary
2025 – 2026 Net Sales Summary ($ in millions) 2026 2025 Q1 Q2 Q1 Q2 Q3 Q4 FY Ecommerce 19.2 20.5 16.8 18.1 19.0 20.2 74.1 Watson’s & Other B2B 3.2 3.6 4.7 4.6 7.0 7.3 23.6 Total Tru Niagen 22.4 24.2 21.5 22.7 26.0 27.5 97.7 Food-grade Niagen 7.3 4.9 7.0 6.0 6.4 4.7 24.1 Pharmaceutical-grade Niagen 0
Slide 11: Key P&L Metrics
Key P&L Metrics Three Months Ended June 30, Six Months Ended June 30, ($ in thousands) 2026 2025 2026 2025 Net Sales 29,785 31,117 61,259 61,598 Gross Profit 19,314 20,226 39,290 39,557 % of Net Sales 64.8% 65.0% 64.1% 64.2% Sales and Marketing 10,130 8,207 19,805 16,324 % of Net Sales 34.0% 26.4% 3
Slide 12: Adjusted EBITDA Summary
Adjusted EBITDA Summary Reconciliation of Non-GAAP Financial Measures (In thousands) Three Months Ended FY Three Months Ended Q1 2025 Q2 2025 Q3 2025 Q4 2025 2025 Q1 2026 Q2 2026 Net income, as reported $ 5,063 $ 3,609 $ 4,578 $ 4,132 $ 17,382 $ 6,318 $ 963 Adjustments Interest income, net (459) (55
Slide 13: Quarterly Balance Sheet Highlights
Quarterly Balance Sheet Highlights (in thousands) 6/30/25 9/30/25 12/31/25 3/31/26 6/30/26 Key Drivers Since Year-End (Q4 2025 vs Q2 2026) Up $2.0 million primarily driven by positive operating results and Cash $60,474 $64,290 $64,788 $66,549 $66,740 proceeds from the sale of the non-core business,
Slide 14: Cash Flow Highlights
Cash Flow Highlights Three Months Ended Three Months Ended Six Months Ended FY 2025 (in thousands) June 30, 2026 3/31/25 6/30/25 9/30/25 12/31/25 3/31/26 6/30/26 Net Income $5,063 $3,609 $4,578 $4,132 $17,382 $6,318 $963 $7,281 Working Capital Changes 2,681 (4,399) (3,004) (3,669) (8,391) (5,017) (3
Slide 15: The Science
The Science 15 The information contained in this documents is confidential, privileged and only for the information of the intended recipient and may not be used, published or redistributed without the prior written consent (2019)
Slide 16: Scientific Advisory Board
Scientific Advisory Board 16
Slide 17: Clinical Studies on Oral Niagen in Multiple Health Areas
Clinical Studies on Oral Niagen® in Multiple Health Areas Note: Highlighted achievements in duration, participation, and dosage only consider peer-reviewed, published studies. Status of clinical studies presented as of July 23, 2026. 17
Slide 18: Contact Info
Contact Info: Niagen Bioscience Investor Relations: KCSA Strategic Communications Valter Pinto, Managing Director T: +1 (212) 896-1254 Niagen@kcsa.com www.niagenbioscience.com Where to purchase Tru Niagen® TruNiagen.com Find Health Clinics Offering Niagen® Plus NiagenPlus.com The information contain